Phase II trial of pirfenidone in adults with neurofibromatosis type 1 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Neurofibromatosis 1
  • Pyridones

abstract

  • We performed an open-label phase II trial of oral pirfenidone in 24 patients with neurofibromatosis type 1 (NF1). Tumors were monitored by three-dimensional MRI. At the end of treatment, four patients had a decrease in tumor volume by 15% or more, three had tumor progression, and 17 remained stable. Pirfenidone warrants further investigation in NF1, which has until now lacked an effective control therapy.

publication date

  • November 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1212/01.wnl.0000243231.12248.67

PubMed ID

  • 17035676

Additional Document Info

start page

  • 1860

end page

  • 2

volume

  • 67

number

  • 10